Tumor necrosis factor alpha-inducible protein 3 (TNFAIP3) encodes a ubiquitin-modifying protein, A20, that is a critical regulator of inflammatory responses. TNFAIP3 polymorphisms are associated with the susceptibility to multiple autoimmune diseases (AIDs) including psoriasis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and celiac disease. In order to refine the TNFAIP3 association signal in psoriasis and identify candidate causal variants, we performed imputation and meta-analysis of the TNFAIP3 region in five European ancestry cohorts totaling 4704 psoriasis cases and 7805 controls. We identified 49 variants whose significance exceeded a corrected Bonferroni threshold, with the top variant being rs582757 (P = 6.07 × 10 − 12 , odds ratio (OR) = 1.23). Conditional analysis revealed a suggestive independent association at rs6918329 (P cond = 7.22 × 10 − 5 , OR = 1.15). Functional annotation of the top variants identified several with a strong evidence of regulatory potential and several within long noncoding RNAs. Analysis of TNFAIP3 haplotypes revealed that the psoriasis risk haplotype is distinct from other AIDs. Overall, our findings identify novel candidate causal variants of TNFAIP3 in psoriasis and highlight the complex genetic architecture of this locus in autoimmune susceptibility.
INTRODUCTION
Psoriasis is an autoimmune inflammatory skin disorder, which ranges in severity from isolated scaling erythematosus plaques on the joints or scalp to almost complete coverage of the skin's surface. A worldwide prevalence of 2-4% has been reported with higher prevalence rates in populations of European descent and populations in higher latitudes. 1 Currently, 40 independent loci are associated with the development of psoriasis. 2 Psoriasis susceptibility shares genetic overlap with several other autoimmune diseases (AIDs) such as Crohn's disease. 3 One of the most robust psoriasis associations is with a region harboring the gene for tumor necrosis factor alpha-inducible protein 3 (TNFAIP3). This is of high interest because variants in TNFAIP3 are also associated with susceptibility to systemic lupus erythematosus (SLE), 4, 5 rheumatoid arthritis (RA), 6 systemic sclerosis (SSc) 7 and celiac disease (CD). 8 TNFAIP3 encodes the A20 protein, which downregulates inflammation by restricting NF-kB pathway signaling downstream of tumor necrosis factor receptor 1, CD40, Toll-like receptors, NOD-like receptors and the interleukin-1 receptor.
9 A20-deficient mice develop a severe autoimmune phenotype with organ inflammation, cachexia and premature death. 10 As TNFAIP3 may serve as a master regulator of autoimmunity, identifying the causal genetic variants associated with AIDs is of prime interest.
In the initial psoriasis genome-wide association studies (GWAS), the intronic TNFAIP3 single-nucleotide polymorphism (SNP) rs610604 was the most significantly associated variant identified. 11 However, whether rs610604 is the causal variant was unknown. To further refine the susceptibility signals in psoriasis and to identify potential functional variants in the TNFAIP3 region, we performed imputation and meta-analysis of five case-control psoriasis cohorts, three of which were used in previously published GWAS. Our large fine-mapping study of the TNFAIP3 region in psoriasis included a total of 4704 cases and 7805 controls.
RESULTS

Association testing
We performed a meta-analysis of the TNFAIP3 region, encompassing TNFAIP3 ± 250 kb, in five European ancestry psoriasis cohorts totaling 4704 cases and 7805 controls (Table 1) . We optimized the density and accuracy of SNP imputation using a combined reference panel from the DCEG (Division of Cancer Epidemiology and Genetics) 12 and 1000 Genomes phase 3 resulting in 3815 variants that were analyzed (Supplementary Table 1 ). Association testing identified 43 variants whose significance exceeded a strict Bonferroni threshold of P o 1.3 × 10 − 5 (Table 2 ) and 49 variants whose significance exceeded an adjusted Bonferroni threshold of Po 5.3 × 10 − 5 that accounts for the linkage disequilibrium (LD) between nearby SNPs (see Materials and Methods). The most significant variant using a random-effects model was rs582757 (P = 6.07 × 10 − 12 , odds ratio (OR) = 1.23), which is located within an intron of TNFAIP3 (Figure 1a ). This SNP is as significantly associated with psoriasis risk as the lead SNP reported in several previous GWA studies, rs610604 (P = 8.13 × 10 − 12 , OR = 1.22).
To identify potential additional independent signals in the TNFAIP3 region, we performed conditional association testing. After conditioning on the top variant, rs582757, the most significant SNP was rs6918329 (P cond = 7.22 × 10 − 5 , OR = 1.15), whose P-value was very close to the adjusted Bonferroni significance threshold (Figure 1b ). This SNP is located~35 kb upstream of the TNFAIP3 mRNA start site. Conditioning on the top two SNPs, rs582757 and rs6918329, yielded residual peaks that did not cross the adjusted Bonferroni threshold (Figure 1c) . The metaanalysis and conditional testing was also performed using a fixedeffects model but the results did not differ greatly from the random-effects model. We report the results of the random-effects model as it is more conservative since it does not assume the same effect size across studies. 14 
Identification of candidate causal variants
We cross-referenced top SNPs exceeding the Bonferroni significance in the TNFAIP3 region (Table 2 ) with a variety of bioinformatics databases to identify SNPs with evidence of functionality. We utilized RegulomeDB, 15 a database that pools functional data from sources such as the Encyclopedia of DNA Elements, manual annotations and experimental data sets including DNase-seq, DNase footprinting, transcription factor (TF) ChIP-seq, histone ChIP-seq, expression quantitative trait loci analyses, DNase I sensitivity QTLs analyses, ChIP-exo data and validated enhancer regions. RegulomeDB contains 460 million annotations derived from 962 experimental data sets and for any queried SNP computes a prediction score from 1-6 for evidence of functional significance, with a score of 1 indicating the highest evidence of functionality, 6 indicating the least evidence and 7 indicating that no data is available. We also evaluated our top TNFAIP3 SNPs using a newly developed metric for variant pathogenicity 16 and an expanded database 17 containing the positions of long noncoding RNAs (lncRNAs), as variants within such lncRNAs could impact lncRNA function. 18 Finally, we examined our SNPs for an evidence of evolutionary conservation.
We first used RegulomeDB to examine SNPs in high LD with our most highly associated SNP, rs582757, which we refer to as 'Signal 1'. rs582757 itself had a RegulomeDB score of 5, which corresponds to minimal evidence of TF binding. However, rs598493, a SNP in nearly perfect LD with rs582757 (r 2 = 0.99), had a RegulomeDB score of 3a, which corresponds to empiric evidence of TF binding to NFKB1, IRF4 and SMARCA4, location within a TF DNA-binding motif and location within a region of DNase hypersensitivity (Table 2) . Interestingly, the previously reported lead GWAS SNP, rs610604, was also in high LD with rs582757 (r 2 = 0.80) and had a RegulomeDB score of 4, corresponding to evidence of TF binding plus location within a region of DNase hypersensitivity.
We next examined SNPs in high LD with rs6918329 ('Signal 2'), the most highly associated SNP after conditioning on rs582757.
Although rs6918329 itself showed little evidence of regulatory function (RegulomeDB score of 6), rs9494879, a SNP in perfect LD (r 2 = 1.0) with rs6918329, had a RegulomeDB score of 2c, indicating high likelihood of regulatory function ( Table 2 ). This SNP has been shown to be a TF-binding site for the proteins FOXA1, FOXA2, CDX2 and HNF4A through ChIP-seq and contains a matched TF motif and DNase hypersensitivity peak. 19, 20 rs9494879 is located within a large 44-kb long noncoding RNA, LOC100130476 (Figures 1a and c) , whose function is not known and which is in close proximity to TNFAIP3. Thus, rs9494879 could potentially regulate TNFAIP3, LOC100130476 or both.
We also identified several SNPs in moderate LD (r 2 = 0.5-0.7) with both Signal 1 and Signal 2 that had significant P-values and displayed functional potential. Three SNPs-rs601035 (P = 2.68 × 10 − 9 ), rs1561121 (P = 1.43 × 10 − 7 ) and the dinucleotide deletion chr6:138151315 (P = 4.36 × 10 − 8 )-were found to be located within long intergenic noncoding RNAs 17 in the TNFAIP3 region. Another SNP, rs111355666 (P = 3.09 × 10 − 8 ), was also in moderate LD with both Signal 1 and Signal 2 and had a RegulomeDB score of 3a, owing to the potential SPI1 binding, location within a TF binding motif, and location within a DNase hypersensitive region. Recently, the Combined AnnotationDependent Depletion method 16 has been developed to estimate the relative deleteriousness of genetic variants according to a C-score, with a larger C-score indicative of higher pathogenic potential. Two variants among our highly associated variants, rs629953 (P = 3.95 × 10 Table 2 ). Finally, we also examined our top variants for conservation across mammalian species using phastCons scores but this did not reveal any evidence of high conservation of these sequences.
All together, we have identified a number of SNPs in the TNFAIP3 region with dual evidence of significant statistical association with psoriasis and evidence of potential functionality. These SNPs serve as candidate causal SNPs for psoriasis in the TNFAIP3 region.
Haplotype analysis Haplotype analysis of the top two independent risk variants, rs582757 and rs6918329, identified four main haplotypes present within the European population ( Figure 2 ). H2, the most detrimental risk haplotype containing the minor alleles of both SNPs, had a frequency of 23% in the European population and conferred a psoriasis OR of 1.23. Haplotype H4, containing the minor allele of rs582757 but major allele of rs6918329, had a frequency of 8% and conferred a psoriasis OR of 1.16. To determine the relationship between the TNFAIP3 psoriasis risk haplotypes identified in this study and the TNFAIP3 risk haplotypes identified in other AIDs, we examined previously Cases were typed on 660W Quad and controls were typed on 1.2 mil. This data set represents the overlap of SNPs that is 519 K.
TNFAIP3 meta-analysis in psoriasis J Nititham et al Table 2 . published TNFAIP3 risk haplotypes associated with SLE, RA, SSc and CD (Table 3 ). The SLE risk haplotype is tagged by the minor alleles of the two variants, rs5029939(G)-rs2230926(G) and confers an OR in SLE of 1.71, P = 8.7 × 10 − 10 .
4 Surprisingly, when we examined the SLE risk haplotype in our psoriasis data set, we found that the SLE risk haplotype conferred a protective effect in psoriasis (OR = 0.81, 95% CI 0.70-0.95, P = 0.0068). Similarly, as SLE and SSc share several risk SNPs, the SSc haplotype (OR = 2.88, P = 2.63x10 − 6 in SSc) also conferred protection in psoriasis (OR = 0.8, P = 0.007). 7 When we examined four RA haplotypes (RA1-RA4) in psoriasis, we found that risk or protection in RA did not confer similar risk or protection in psoriasis. 6 As in RA, the SNP associated with risk in CD, rs2327832(G), did not confer risk in psoriasis. 8 Thus, none of the TNFAIP3 risk haplotypes in four other AIDs conferred risk of psoriasis, and in some cases, appeared to confer protection against psoriasis. DISCUSSION TNFAIP3 appears to be a central player in the regulation of autoimmunity as genetic variants at this locus have been associated with the susceptibility to SLE, RA, SSc, CD and psoriasis. Here, to refine the association signal in psoriasis, we performed an imputation and meta-analysis of the TNFAIP3 region in 4704 psoriasis cases and 7805 controls. To maximize imputation accuracy, we utilized a combined reference panel of 1000 Genomes Phase 3 and DCEG, with the latter having been shown to provide enhanced imputation accuracy compared with 1000 Genomes/HapMap alone. 12 We identified 49 variants whose significance exceeded an adjusted Bonferroni significance threshold. Our top hit was rs582757 (P = 6.07 × 10 − 12 , OR = 1.23), located within an intron of TNFAIP3. rs582757 had a lower P-value than rs610604 (P = 8.13 × 10 − 12 , OR = 1.22), the index SNP originally identified in GWA studies of psoriasis. 11, 13 Conditional analysis on rs582757 identified another SNP with suggestive evidence of association, rs6918329 (P cond = 7.22 × 10
, OR = 1.15). Thus, our analysis suggests that there may be two independent psoriasis associations at the TNFAIP3 locus.
Another meta-analysis of psoriasis that included Immunochip data also identified rs582757 as the top SNP at the TNFAIP3 locus. 21 However, that study did not conduct fine-mapping or conditional analysis of the TNFAIP3 association. Interestingly, our analysis suggests that rs582757 is not the most probable causal SNP at the TNFAIP3 locus, with rs598493 (RegulomeDB score of 3a) more likely to be functional. Similarly, within our second association peak we identified rs9494879 (RegulomeDB score of 2c and location within a long noncoding RNA) as a SNP with a high evidence of functionality.
One of the most surprising results of our study was that the TNFAIP3 risk haplotype in psoriasis did not correspond to the TNFAIP3 risk haplotypes seen in SLE, RA, SSc or CD. In fact, the risk haplotypes in SLE and SSc were protective in psoriasis. The expression of TNFAIP3 in different cell types might be regulated by different genetic variants, and cell lineage-specific expression of TNFAIP3 might determine different autoimmune phenotypes. Indeed, the recent development of mice with lineage-specific deletions of TNFAIP3 has shed light on the potential role of TNFAIP3 in different autoimmune phenotypes. Mice with deletion of TNFAIP3 in B cells showed increased plasma cells, IgM and IgG autoantibody production, and renal immunoglobulin deposition that corresponds to the features seen in human SLE. 22, 23 Mice with deletion of TNFAIP3 in dendritic cells demonstrated dendritic cell activation, expansion of T cells, and either autoantibody production and nephritis similar to SLE 24 or colitis and seronegative arthritis similar to inflammatory bowel disease. 25 Similarly, targeted deletion of TNFAIP3 in intestinal epithelial cells results in mice with hypersensitivity to experimental colitis. 26 Mice with deletion of TNFAIP3 in macrophages and granulocytes developed spontaneous polyarthritis and collagen-specific autoantibodies reminiscent of RA. 27 Finally, targeted deletion of TNFAIP3 in keratinocytes led to mice with keratinocyte hyperproliferation, disheveled hair and sebocyte hyperplasia, but no inflammation. 28 Together these studies suggest that the dysregulation of TNFAIP3 in different cell types may lead to different clinical outcomes. Therefore, our identification of a distinct psoriasis risk haplotype for TNFAIP3 suggests the possibility that this haplotype might act on different cell types or a combination of cell types compared with other AIDs. Alternatively, the psoriasis risk haplotype might influence differential temporal expression of TNFAIP3.
In summary, through imputation and meta-analysis of a large number of psoriasis cases and controls, we have identified two probable independent association signals in the TNFAIP3 region corresponding to a select number of candidate causal variants. Comparison of our psoriasis data to other AIDs revealed that the psoriasis risk haplotype is distinct from other TNFAIP3 risk variants observed in SLE, RA, SSc and CD. Our work has highlighted the complex genetic architecture of this locus in autoimmune susceptibility.
MATERIALS AND METHODS Cohorts
The five studies in our meta-analysis consisted of data used in three previously published GWAS and one unpublished GWAS, and one additional case-control cohort for which a dense SNP panel was available in the TNFAIP3 region. 11, 13, 29 All studies were comprised of individuals of self-reported European descent. Table 1 describes these five studies in detail. Two of the GWAS cohorts are North American, the third is from Sweden and the fourth is the psoriasis set from the WTCCC2 (Wellcome Trust Case Control Consortium 2) from the United Kingdom. The additional case-control cohort that was typed on the Illumina GoldenGate panel consisted of North American psoriasis cases diagnosed by a dermatologist and healthy controls recruited at University of California San Francisco and Washington University in St Louis.
Quality control
In the four GWA studies, common quality-control filters were applied to each of the GWAS cohorts. We filtered out individuals who have o93% of complete genotypes, removed SNPs that have o95% complete genotypes, have minor allele frequency (MAF) o1% and failed the Hardy-Weinberg equilibrium test at P o0.001. In the fine-mapping study, we filtered out individuals who have o 90% complete genotypes, SNPs that have o95% of complete genotypes, MAF o1% and failed Hardy-Weinberg equilibrium at Po0.0001.
We performed identity-by-descent analysis (IBD) across all North American cohorts to detect duplicates and first-degree relatives because any of the recruitment sites may have contributed to more than one of the cohorts. Because genome-wide data were available for four of the five studies, analysis was performed in three stages. In the first stage, we started with a set of 78 455 SNPs that were common to all four GWAS platforms. LD pruning at r 2 = 0.25 of this set of 78 455 SNPs reduced the number to 52 615 SNPs, which we then used to run an IBD analysis in PLINK on the two US cohorts. The IBD analysis indicated that there were 11 duplicates to remove and 5 first-degree relatives (pi-hat 40.47). In the second stage, we compared 103 common SNPs between the Illumina GoldenGate Panel and the Illumina 317 K panel (Illumina, San Diego, CA, USA). We had prior knowledge that there were 135 duplicates in the overlap and those 135 were kept in the analysis to confirm that 103 SNPs Population substructure
Principal components analyses (PCA) to identify the ancestry outliers were performed in EIGENSTRAT in three stages in order to incorporate the fine-mapping study. 30 In the first stage of PCA, we used the LD-pruned set of 52 k SNPs common across the four GWAS platforms. At a threshold of sigma 7, which represents seven s.d. from the mean of the per-subject principal component values, we removed eight individuals from the Illumina 317 K study and 31 individuals from the Perlegen 400 k study. We excluded ancestry outliers at a sigma threshold of seven because when graphing the first principal component against the second principal component at a sigma threshold of 6, the threshold removed the Europeans that did not cluster near the Northern Europeans. As there were 7353 individuals from the United Kingdom (WTCCC2 cohort) and 1163 individuals from Sweden, the larger proportion of Northern Europeans narrowed the s.d. In the second stage, we used the 87 ancestry informative markers that were typed as part of the fine-mapping study to run PCA. No individuals were removed at that stage. In the third stage, we used 48 overlapping ancestry informative markers between the GoldenGate panel and the 52 k pruned data set. No additional outliers were removed at that stage from this cohort.
Imputation
We imputed a 250-kb region on each side of TNFAIP3 using Impute2 with a combined reference panel of the observed genotypes in the DCEG reference panel and the phased haplotypes of the 1000 Genomes phase 3. 12, 31 SNPs that were present in the DCEG data set only were removed before imputation. This combined reference panel resulted in 8787 variants imputed in each study. We removed any imputed SNPs that had an information score of o0.3.
Statistical analyses
Using a missing data likelihood score test in SNPTESTv2.4, we performed SNP-association tests using an additive model that accounted for genotype uncertainty and adjusted for the first three PCs in each cohort. 32 After removing the SNPs with no variation and the poorly performing imputed SNPs, there remained 3082 SNPs in Illumina 317 k, 3850 SNPs in Perlegen 400 k, 3136 SNPs in Illumina 550 k, 3816 SNPs in Illumina Quad 6 60/1.2M Duo and 2547 SNPs in the Illumina GoldenGate study. Meta-analysis using a random-effects model was performed in PLINK with 3815 SNPs represented in two or more studies. 33 Upon identifying the most significant SNP in the meta-analysis, we conditioned on that top SNP and adjusted for the first three PCs in each cohort in SNPTEST, and then meta-analyzed those results in PLINK with a random-effects model. The most significant SNP after conditioning on the first then became the second SNP that we adjusted for in the next round of association tests and subsequent meta-analysis. We repeated that process two more times to adjust for the top three SNPs in the fourth round of association tests. To estimate haplotypes and perform haplotype association tests, the genotype dosage data was then converted to a best-guess data set with a threshold of 0.8 for use in Haploview version 4.2. 34 We then compared the risk haplotypes for psoriasis against the risk haplotypes that have been published for other AIDs. To adjust for multiple testing, we applied a modified Bonferroni correction threshold that accounts for the LD structure by determining the number of informative SNPs in the region. As the 3815 SNPs in the TNFAIP3 region are not independent due to LD, we applied a previously published and validated spectral decomposition algorithm to determine the number of the most informative SNPs reducing the 3815 SNPs in the TNFAIP3 region down to 954 informative SNPs thus making our threshold for significance Po 5.3 × 10 − 5 .
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